Age: 78.0
Sex: F
Vaccine: COVID19, COVID19, COVID19, COVID19, COVID19
Symptoms: Biopsy, Condition aggravated, Discomfort, Drug hypersensitivity, Parotitis
Clinical narrative: Sjogren's has gotten significantly more troubling; Sjogren's has gotten significantly more troubling; Lymphocytic dermatitis; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78-year-old female patient received BNT162b2 (BNT162B2), on 18Mar2021 as dose 2, single (Lot number: EN6204) at the age of 78 years for covid-19 immunisation. The patient's relevant medical history included: "Raynauds" (ongoing), notes: She had Raynaud's before receiving the COVID-19 Vaccines. Had Raynaud's with her crest form scleroderma for 30 years but the COVID-19 vaccines made her conditions a lot worse.; "Pulmonary hypertension" (ongoing), notes: Pulmonary hypertension, Diagnosed this fall was borderline for years and now over the borderline.; "Scleroderma" (ongoing), notes: She had scleroderma for 30 years before receiving the COVID-19 Vaccines. She had the crest form scleroderma; "Hashimoto's thyroiditis" (ongoing), notes: Hashimoto's thyroiditis, Diagnosed about 34 years ago; "Sjogren's Reaction Diagnosed between 20 and 30 years ago" (unspecified if ongoing), notes: Sjogren's Reaction Diagnosed between 20 and 30 years ago.; "environmentally allergic Diagnosed about 34 years ago." (unspecified if ongoing), notes: environmentally allergic Diagnosed about 34 years ago.; "High blood pressure" (unspecified if ongoing); "Dry eyes" (unspecified if ongoing); "Anemia" (unspecified if ongoing); "Rash" (unspecified if ongoing); "Probiotic" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: BNT162b2 (Dose 1, Batch/lot number: EN6202), administration date: 26Feb2021, when the patient was 78-year-old, for COVID-19 immunization, reaction(s): "Sjogren's reaction worsening", "total dryness throughout the body"; Shingles vaccine (Did have a severe reaction to a shingles vaccine prior to the COVID-19 vaccine and was advised not to take a second shingles vaccine. Supposedly it was reported by her pharmacist already. Had gotten the old shingles vaccine and was recommended to get the new one and then couldn't do the second dose.), reaction(s): "severe reaction". The following information was reported: SUPERFICIAL INFLAMMATORY DERMATOSIS (non-serious) with onset 2021, outcome "not recovered", described as "Lymphocytic dermatitis"; SJOGREN'S SYNDROME (medically significant), CONDITION AGGRAVATED (medically significant) all with onset 2021, outcome "not recovered" and all described as "Sjogren's has gotten significantly more troubling". Had the COVID-19 Vaccine. Clarified that she had three Pfizer products, the first two and then another one. Each time she had a COVID-19 Vaccine she had a Sjogren's reaction and other symptoms that appeared at the same time which she hadn't had before. The patient was told by her immunologist and neurologist that the reactions are due to the COVID-19 Vaccines most likely. The patient has lymphocytic dermatitis on both legs that she never had before. Clarified the lymphocytic dermatitis appeared shortly after the second COVID-19 vaccine and has not gone away. Her Sjogren's has gotten significantly more troubling. The patient had scleroderma, Sjogren's, and Raynaud's. She was told to not have any more mRNA vaccines. Sjogren's is now better but is still worse than it was before the COVID-19 vaccines. Lymphocytic dermatitis started right after the second COVID-19 Vaccine shot. Intermittently it will improve after she sees her dermatologist. Gets cortisone cream to treat lymphocytic dermatitis and then goes back through the cycle where things aren't improving. The patient stated cortisone cream will improve her lymphocytic dermatitis for a while and then since she has scleroderma she doesn't know what will happen. Clarified that at one point her system goes down again then comes back. Cortisone cream was triamcinolone Acetonide 0.1% 80 gm, apply twice daily up to two weeks per month as needed. The patient was biopsied by her dermatologist to confirm the diagnosis. The event "lymphocytic dermatitis" required physician office visit. The patient underwent the following laboratory tests and procedures: Biopsy: (2021) lymphocytic dermatitis with purpura. Therapeutic measures were taken as a result of superficial inflammatory dermatosis.